Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies

Read more at globenewswire.com